Custom-made cast titanium implants produced with CAD/CAM for the reconstruction of cranium defects.

E. Heissler,F. S. Fischer,S. Bolouri,T. Lehmann,W. Mathar,A. Gebhardt,W. Lanksch,J. Bier

DOI: https://doi.org/10.1016/S0901-5027(98)80060-X

1998-10-01

Abstract:

What problem does this paper attempt to address?

Targeting the DNA Repair Pathway for Breast Cancer Therapy: Beyond the Molecular Subtypes.

Quan Yuan,Sisi Qin,Yang Zhang,Zhuolin Li,Qiao Liang,Ting Long,Weiyun Wang,Dan Zhang,Qing Zhao,Zehua Dai,Qing Ni,Fei Zhao,Wootae Kim,Jun Hou

DOI: https://doi.org/10.1016/j.biopha.2023.115877

IF: 7.419

2023-01-01

Biomedicine & Pharmacotherapy

Abstract:DNA repair is a vital mechanism in cells that protects against DNA damage caused by internal and external factors. It involves a network of signaling pathways that monitor and transmit damage signals, activating various cellular activities to repair DNA damage and maintain genomic integrity. Dysfunctions in this repair pathway are strongly associated with the development and progression of cancer. However, they also present an opportunity for targeted therapy in breast cancer. Extensive research has focused on developing inhibitors that play a crucial role in the signaling pathway of DNA repair, particularly due to the remarkable success of PARP1 inhibitors (PARPis) in treating breast cancer patients with BRCA1/2 mutations. In this review, we summarize the current research progress and clinical implementation of BRCA and BRCAness in targeted treatments for the DNA repair pathway. Additionally, we present advancements in diverse inhibitors of DNA repair, both as individual and combined approaches, for treating breast cancer. We also discuss the clinical application of DNA repair-targeted therapy for breast cancer, including the rationale, indications, and summarized clinical data for patients with different breast cancer subtypes. We assess their influence on cancer progression, survival rates, and major adverse reactions. Last, we anticipate forthcoming advancements in targeted therapy for cancer treatment and emphasize prospective areas of development.
Ionic conducting lanthanide oxides.

G. Adachi,N. Imanaka,S. Tamura

DOI: https://doi.org/10.1021/CR0103064

IF: 62.1

2002-05-15

Chemical Reviews

Abstract:A. Cationic Conductors 2406 1. Lithium Ion Conductors 2406 2. Proton Conductors 2408 3. Divalent Cation Conductors 2410 B. Anionic Conductors 2411 1. Chloride Ion Conductors 2411 2. Oxide Ion Conductors 2412 III. Solid Electrolytes with Rare Earths as Dopants 2415 A. Cationic Conductors 2415 1. Lithium Ion Conductors 2415 2. Sodium Ion Conductors 2416 3. Proton Conductors 2417 B. Anionic Conductors 2417 1. Zirconium Dioxides 2417 2. Bismuth Oxides 2418 3. Thorium Oxides 2419 4. Hafnium Oxides 2419 5. Apatites 2419 IV. Trivalent Cation Conductors 2420 A. Ln3+−â-aluminas and Ln3+−â′′-aluminas 2420 B. â-Alumina-Related Materials 2422 C. Perovskite-Type Structures 2422 D. Sc2(WO4)3-Type Solid Electrolytes 2423 E. NASICON-Type Structures 2425 V. Concluding Remarks 2427 VI. Acknowledgment 2427 VII. References 2427
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

Yvette Drew,Frank T Zenke,Nicola J Curtin

DOI: https://doi.org/10.1038/s41573-024-01060-w

IF: 112.288

2024-11-13

Nature Reviews Drug Discovery

Abstract:The DNA damage response (DDR) is a network of proteins that coordinate DNA repair and cell-cycle checkpoints to prevent damage being transmitted to daughter cells. DDR defects lead to genomic instability, which enables tumour development, but they also create vulnerabilities that can be used for cancer therapy. Historically, this vulnerability has been taken advantage of using DNA-damaging cytotoxic drugs and radiotherapy, which are more toxic to tumour cells than to normal tissues. However, the discovery of the unique sensitivity of tumours defective in the homologous recombination DNA repair pathway to PARP inhibition led to the approval of six PARP inhibitors worldwide and to a focus on making use of DDR defects through the development of other DDR-targeting drugs. Here, we analyse the lessons learnt from PARP inhibitor development and how these may be applied to new targets to maximize success. We explore why, despite so much research, no other DDR inhibitor class has been approved, and only a handful have advanced to later-stage clinical trials. We discuss why more reliable predictive biomarkers are needed, explore study design from past and current trials, and suggest alternative models for monotherapy and combination studies. Targeting multiple DDR pathways simultaneously and potential combinations with anti-angiogenic agents or immune checkpoint inhibitors are also discussed.

pharmacology & pharmacy,biotechnology & applied microbiology
DNA Damage Response Inhibitors: an Avenue for TNBC Treatment

Juan Jin,Zhonghua Tao,Jun Cao,Ting Li,Xichun Hu

DOI: https://doi.org/10.1016/j.bbcan.2021.188521

2021-01-01

Biochimica et Biophysica Acta - Reviews on Cancer

Abstract:The DNA damage response (DDR) is critical for the maintenance of genomic stability by sensing DNA damage, regulating cell cycle and initiating DNA repair. Drugs targeting DDR pathways have been increasingly exploited in treating various tumors. Triple negative breast cancer (TNBC) is a highly heterogeneous and aggressive tumor with constitutive activation of oncogenes, inducing replication stress and DNA damage, which require the DDR for survival. In addition, emerging studies have demonstrated that TNBC harbors aberrant genetic alterations in DDR pathways, such as a high frequency of p53 dysfunction and BRCA1/2 mutations. DDR alterations force TNBC to rely on the existing DDR pathways for survival, and make TNBC particularly sensitive to specific DDR inhibitors, such as high sensitivity of TNBC with BRCA1/2 mutations to PARP inhibitors. This review first and comprehensively covers the current status of the development of DDR inhibitors and discusses the mechanism of targeting the DDR in TNBC. Preclinical and clinical studies on inhibitors of the ATR-CHK1-WEE1 pathway and PARP inhibitors, the most studied inhibitors, and some other DDR inhibitors as monotherapy or combination therapy in TNBC are summarized. We also highlight the possible predictive biomarkers for these DDR inhibitors and their potential combination strategies with chemotherapy, radiotherapy or other targeted agents to optimize the efficacy of DDR inhibitors in TNBC treatment. In conclusion, this review discussed the recent considerations related to the use of DDR inhibitors for TNBC and provides a perspective to address future directions and potential therapeutic strategies for patients with TNBC.
Targeting DNA damage response pathways in cancer

Florian J. Groelly,Matthew Fawkes,Rebecca A. Dagg,Andrew N. Blackford,Madalena Tarsounas

DOI: https://doi.org/10.1038/s41568-022-00535-5

IF: 78.5

2022-12-06

Nature Reviews Cancer

Abstract:Cells have evolved a complex network of biochemical pathways, collectively known as the DNA damage response (DDR), to prevent detrimental mutations from being passed on to their progeny. The DDR coordinates DNA repair with cell-cycle checkpoint activation and other global cellular responses. Genes encoding DDR factors are frequently mutated in cancer, causing genomic instability, an intrinsic feature of many tumours that underlies their ability to grow, metastasize and respond to treatments that inflict DNA damage (such as radiotherapy). One instance where we have greater insight into how genetic DDR abrogation impacts on therapy responses is in tumours with mutated BRCA1 or BRCA2 . Due to compromised homologous recombination DNA repair, these tumours rely on alternative repair mechanisms and are susceptible to chemical inhibitors of poly(ADP-ribose) polymerase (PARP), which specifically kill homologous recombination-deficient cancer cells, and have become a paradigm for targeted cancer therapy. It is now clear that many other synthetic-lethal relationships exist between DDR genes. Crucially, some of these interactions could be exploited in the clinic to target tumours that become resistant to PARP inhibition. In this Review, we discuss state-of-the-art strategies for DDR inactivation using small-molecule inhibitors and highlight those compounds currently being evaluated in the clinic.

oncology
Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Yongjian Zhu,Jue Hu,Yiduo Hu,Weiguo Liu

DOI: https://doi.org/10.1016/j.ctrv.2009.06.005

IF: 13.608

2009-01-01

Cancer Treatment Reviews

Abstract:Increased chemo-resistance and radio-resistance of cancer cells is a major obstacle in the treatment and management of malignant cancers. An important mechanism that underlies the development of such therapeutic resistance is that cancer cells recognize DNA lesions induced by DNA-damaging agents and by ionizing radiation, and repair these lesions by activating various DNA repair pathways. Therefore, Use of pharmacological agents that can inhibit certain DNA repair pathways in cancer cells has the potential for enhancing the targeted cytotoxicity of anticancer treatments and reversing the associated therapeutic resistance associated with DNA repair; such agents, offering a promising opportunity to achieve better therapeutic efficacy. Here we review the major DNA repair pathways and discuss recent advances in the development of novel inhibitors of DNA repair pathways; many of these agents are under preclinical/clinical investigation.
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

Binbin Cheng,Wei Pan,Yi Xing,Yao Xiao,Jianjun Chen,Zheng Xu

DOI: https://doi.org/10.1016/j.ejmech.2022.114109

IF: 7.088

2022-02-01

European Journal of Medicinal Chemistry

Abstract:DDR (DNA damage response) defects in cells drive tumor formation by promoting DNA mutations, which also provides cancer-specific vulnerabilities that can be targeted by synthetic lethality-based therapies. Until now, PARP inhibitors like olaparib are the first successful case of utilizing synthetic lethality-based therapy to treat cancers with DNA-repairing deficiency (e.g. BRCA1 or BRCA2 mutation), which has fueled the search for more targetable components in the DDR signaling pathway by exploiting synthetic lethality, including but not limited to DNA-PK, ATR, ATM, CHK1, and WEE1. After years of efforts, numerous DDR kinase inhibitors have been discovered. Some of them are being investigated in clinical trials and have shown promising results for cancer therapy. In this review, we summarize the latest advancement in the development of DDR kinase inhibitors including those in preclinical stages and clinical trials, the crystal structures of DDR enzymes, and binding modes of inhibitors with target proteins. The biological functions involving different genes and proteins (ATR, DNA-PK, ATM, PARP, CHK1, and WEE1) are also elucidated.

chemistry, medicinal
Targeting the DNA damage response in hematological malignancies

Sanjay De Mel,Ainsley Ryan Lee,Joelle Hwee Inn Tan,Rachel Zi Yi Tan,Li Mei Poon,Esther Chan,Joanne Lee,Yen Lin Chee,Satish R. Lakshminarasappa,Patrick William Jaynes,Anand D. Jeyasekharan

DOI: https://doi.org/10.3389/fonc.2024.1307839

IF: 4.7

2024-01-29

Frontiers in Oncology

Abstract:Deregulation of the DNA damage response (DDR) plays a critical role in the pathogenesis and progression of many cancers. The dependency of certain cancers on DDR pathways has enabled exploitation of such through synthetically lethal relationships e.g., Poly ADP-Ribose Polymerase (PARP) inhibitors for BRCA deficient ovarian cancers. Though lagging behind that of solid cancers, DDR inhibitors (DDRi) are being clinically developed for haematological cancers. Furthermore, a high proliferative index characterize many such cancers, suggesting a rationale for combinatorial strategies targeting DDR and replicative stress. In this review, we summarize pre-clinical and clinical data on DDR inhibition in haematological malignancies and highlight distinct haematological cancer subtypes with activity of DDR agents as single agents or in combination with chemotherapeutics and targeted agents. We aim to provide a framework to guide the design of future clinical trials involving haematological cancers for this important class of drugs.

oncology
Targeting DNA Repair Pathways: Mechanisms and Potential Applications in Cancer Therapy

Bai Yongtai,Wang Weibin,Wang Jiadong

DOI: https://doi.org/10.1007/s42764-020-00026-7

2020-01-01

Genome Instability & Disease

Abstract:DNA damage can be caused by both endogenous and environmental factors, such as replication errors, reactive oxygen species (ROS) and chemotherapeutic drugs. Accurate and effective repair of DNA damage can preserve the integrity of the genome. However, if left unrepaired or repaired inappropriately, DNA damage could lead to the development of a variety of diseases, including cancers. DNA damage response (DDR) pathways are regarded as attractive tumor therapeutic targets. In recent years, representative drugs like poly(ADP-ribose) (PAR) polymerase inhibitors (PARPis) target DNA damage repair pathways and thus have generated profound breakthroughs in the treatment of tumors. Therefore, it is necessary to understand the mechanisms behind these drugs for treating tumors. In this review, we will discuss the mechanisms of representative tumor therapeutic drugs in the field of DNA damage repair and our current understanding of the related inhibitors that are expected to be used in future cancer therapies. We believe that these underlying mechanisms will provide significant support for directing drug use and future drug development.
Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers

Martin Liptay,Joana S. Barbosa,Sven Rottenberg

DOI: https://doi.org/10.3389/fonc.2020.00670

IF: 4.7

2020-05-05

Frontiers in Oncology

Abstract:Most cancers have lost a critical DNA damage response (DDR) pathway during tumor evolution. These alterations provide a useful explanation for the initial sensitivity of tumors to DNA-targeting chemotherapy. A striking example is dysfunctional homology-directed repair (HDR), e.g., due to inactivating mutations in BRCA1 and BRCA2 genes. Extensive efforts are being made to develop novel targeted therapies exploiting such an HDR defect. Inhibitors of poly(ADP-ribose) polymerase (PARP) are an instructive example of this approach. Despite the success of PARP inhibitors, the presence of primary or acquired therapy resistance remains a major challenge in clinical oncology. To move the field of precision medicine forward, we need to understand the precise mechanisms causing therapy resistance. Using preclinical models, various mechanisms underlying chemotherapy resistance have been identified. Restoration of HDR seems to be a prevalent mechanism but this does not explain resistance in all cases. Interestingly, some factors involved in DNA damage response (DDR) have independent functions in replication fork (RF) biology and their loss causes RF instability and therapy sensitivity. However, in BRCA-deficient tumors, loss of these factors leads to restored stability of RFs and acquired drug resistance. In this review we discuss the recent advances in the field of RF biology and its potential implications for chemotherapy response in DDR-defective cancers. Additionally, we review the role of DNA damage tolerance (DDT) pathways in maintenance of genome integrity and their alterations in cancer. Furthermore, we refer to novel tools that, combined with a better understanding of drug resistance mechanisms, may constitute a great advance in personalized diagnosis and therapeutic strategies for patients with HDR-deficient tumors.

oncology
Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

Wei Sun,Qing Zhang,Runkun Wang,Yang Li,Yue Sun,Lin Yang

DOI: https://doi.org/10.3389/fonc.2021.648687

IF: 4.7

2021-05-07

Frontiers in Oncology

Abstract:DNA damage repair (DDR) pathways play an essential role in maintaining genomic integrity. DDR dysfunction leads to accumulated DNA damage, predisposition to cancer, and high sensitivity to chemotherapy and radiotherapy. Recent studies have demonstrated that DDR status is associated with response to immune checkpoint inhibitors (ICIs). Among the DDR pathways, mismatch repair is one of the most recognized predictive biomarkers for ICIs. Furthermore, preclinical and early clinical studies suggest the rationale of combining agents targeting the DDR pathways, such as poly (ADP-ribose) polymerase (PARP) inhibitors, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, and ataxia telangiectasia and rad3-related (ATR) kinase inhibitors, with ICIs. In the present review, we describe the predictive role of DDR pathways in ICIs and summarize the advances in potential combination strategies of novel agents targeting DDR with ICIs for cancer treatment.

oncology
When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity

Dong Pan,Qi Wang,Aihua Shen,Zhihao Qi,Chunfu Zheng,Burong Hu

DOI: https://doi.org/10.1002/ijc.34954

2024-04-26

International Journal of Cancer

Abstract:DNA damage is a prevalent phenomenon in the context of cancer progression. Evidence suggests that DNA damage responses (DDR) are pivotal in overcoming tumor immune evasion. Alternatively, traditional radiotherapy and chemotherapy operate by inducing DNA damage, consequently stimulating the immune system to target tumors. The intricate interplay between signaling pathways involved in DDR and immune activation underscores the significance of considering both factors in developing improved immunotherapies. By delving deeper into the mechanisms underlying immune activation brought on by DNA damage, it becomes possible to identify novel treatment approaches that boost the anticancer immune response while minimizing undesirable side effects. This review explores the mechanisms behind DNA damage‐induced antitumor immune responses, the importance of DNA damage in antitumor immunity, and potential therapeutic approaches for cancer immunotherapy targeting DDR. Additionally, we discuss the challenges of combination therapy and strategies for integrating DNA damage‐targeting therapies with current cancer immunotherapy. In summary, this review highlights the critical role of DNA damage in tumor immunology, underscoring the potential of DDR inhibitors as promising therapeutic modalities for cancer treatment.

oncology
Abstract IA017: Drugging the DNA damage response (DDR) in the Clinic: Going beyond the approved PARP inhibitors

Timothy A. Yap

DOI: https://doi.org/10.1158/1538-7445.dnarepair24-ia017

IF: 11.2

2024-01-10

Cancer Research

Abstract:Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA damage response (DDR) and/or increased replication stress. These alterations promote the clonal evolution of cancer cells via the accumulation of driver aberrations, including gene copy-number changes, rearrangements, and mutations; however, these same defects also create vulnerabilities that are relatively specific to cancer cells, which could potentially be exploited to increase the therapeutic index of anticancer treatments and thereby improve patient outcomes. The discovery that BRCA-mutant cancer cells are exquisitely sensitive to inhibition of poly(ADP-ribose) polymerase has ushered in a new era of research on biomarker-driven synthetic lethal treatment strategies for different cancers. The therapeutic landscape of antitumor agents targeting the DDR has rapidly expanded to include inhibitors of other key mediators of DNA repair and replication, such as ATR, ATM, CHK1, WEE1, PKMYT1 and PARG. Efforts to optimize these therapies are ongoing across a range of cancers, involving the development of predictive biomarker assays of response (beyond BRCA mutations), assessment of the mechanisms underlying intrinsic and acquired resistance, and evaluation of rational combinations to improve patient outcomes and widen the application of DDR agents. Citation Format: Timothy A. Yap. Drugging the DNA damage response (DDR) in the Clinic: Going beyond the approved PARP inhibitors [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Damage Repair: From Basic Science to Future Clinical Application; 2024 Jan 9-11; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2024;84(1 Suppl) nr IA017.

oncology
Abstract MS1-3: Targeting DNA damage response and HRD in breast cancer

TA Yap

DOI: https://doi.org/10.1158/1538-7445.sabcs21-ms1-3

IF: 11.2

2022-02-15

Cancer Research

Abstract:Abstract Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA damage response (DDR) and/or increased replication stress. These alterations promote the clonal evolution of cancer cells via the accumulation of driver aberrations, including gene copy-number changes, rearrangements and mutations; however, these same defects also create vulnerabilities that are relatively specific to cancer cells, which could potentially be exploited to increase the therapeutic index of anticancer treatments and thereby improve patient outcomes. The discovery that BRCA-mutant cancer cells are exquisitely sensitive to inhibition of poly(ADP-ribose) polymerase has ushered in a new era of research on biomarker-driven synthetic lethal treatment strategies for breast and other cancers. The therapeutic landscape of antitumor agents targeting the DDR has rapidly expanded to include inhibitors of other key mediators of DNA repair and replication, such as ATR, WEE1, ATM, PK-MYT1, DNA-PK, POLQ and USP1. Efforts to optimize these therapies are ongoing across a range of cancers, involving the development of predictive biomarker assays of responsiveness (beyond BRCA mutations), assessment of the mechanisms underlying intrinsic and acquired resistance, and evaluation of rational, tolerable combinations with standard-of-care treatments, novel molecularly targeted agents and immune-checkpoint inhibitors. Citation Format: TA Yap. Targeting DNA damage response and HRD in breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr MS1-3.

oncology
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer

Rui-Xue Huang,Ping-Kun Zhou

DOI: https://doi.org/10.1038/s41392-020-0150-x

IF: 39.3

2020-05-01

Signal Transduction and Targeted Therapy

Abstract:Abstract Radiotherapy is one of the most common countermeasures for treating a wide range of tumors. However, the radioresistance of cancer cells is still a major limitation for radiotherapy applications. Efforts are continuously ongoing to explore sensitizing targets and develop radiosensitizers for improving the outcomes of radiotherapy. DNA double-strand breaks are the most lethal lesions induced by ionizing radiation and can trigger a series of cellular DNA damage responses (DDRs), including those helping cells recover from radiation injuries, such as the activation of DNA damage sensing and early transduction pathways, cell cycle arrest, and DNA repair. Obviously, these protective DDRs confer tumor radioresistance. Targeting DDR signaling pathways has become an attractive strategy for overcoming tumor radioresistance, and some important advances and breakthroughs have already been achieved in recent years. On the basis of comprehensively reviewing the DDR signal pathways, we provide an update on the novel and promising druggable targets emerging from DDR pathways that can be exploited for radiosensitization. We further discuss recent advances identified from preclinical studies, current clinical trials, and clinical application of chemical inhibitors targeting key DDR proteins, including DNA-PKcs (DNA-dependent protein kinase, catalytic subunit), ATM/ATR (ataxia–telangiectasia mutated and Rad3-related), the MRN (MRE11-RAD50-NBS1) complex, the PARP (poly[ADP-ribose] polymerase) family, MDC1, Wee1, LIG4 (ligase IV), CDK1, BRCA1 (BRCA1 C terminal), CHK1, and HIF-1 (hypoxia-inducible factor-1). Challenges for ionizing radiation-induced signal transduction and targeted therapy are also discussed based on recent achievements in the biological field of radiotherapy.

biochemistry & molecular biology,cell biology
Alterations of DNA damage repair in cancer: from mechanisms to applications

Minlin Jiang,Keyi Jia,Lei Wang,Wei Li,Bin Chen,Yu Liu,Hao Wang,Sha Zhao,Yayi He,Caicun Zhou

DOI: https://doi.org/10.21037/atm-20-2920

IF: 3.616

2020-12-01

Annals of Translational Medicine

Abstract:DNA damage repair (DDR) pathways are essential to ensure the accurate transmission of genetic material. However, different endogenous and exogenous factors challenge genomic integrity. Mechanisms involved in the alterations of DDR pathways mainly include genetic inactivation and epigenetic mechanisms. The development and progression of carcinomas are closely associated with DDR pathway aberrations, including the epigenetic silencing of gene O6-alkylguanine-DNA methyltransferase (MGMT); deficiencies of mismatch repair (MMR) genes, including MutL homolog 1 (MLH1), MutS protein homologue (MSH)-2 (MSH2), MSH6, and PMS1 homolog 2; the mismatch repair system component (PMS2); and mutations of homologous recombination repair (HRR) genes, such as the breast cancer susceptibility gene 1/2 (BRCA1/2). Understanding the underlying mechanisms and the correlations between alterations to DDR pathways and cancer could improve the efficacy of antitumor therapies. Emerging evidence suggests that survival is higher in patients with DDR-deficient tumors than in those with DDR-proficient tumors. Thus, DDR alterations play a predictive and prognostic role in anticancer therapies. Theoretical studies on the co-administration of DDR inhibitors and other anticancer therapies, including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, and epigenetic drugs, hold promise for cancer treatments. In this review, we focus on the basic mechanisms, characteristics, current applications, and combination strategies of DDR pathways in the anticancer field.

oncology,medicine, research & experimental
Recent Progress in DNA Damage Response-Targeting PROTAC Degraders

Binbin Cheng,Xiaoting Fei,Zongbao Ding,Xiaopeng Peng,Zhenhong Su,Wei Pan,Jianjun Chen

DOI: https://doi.org/10.1021/acs.jmedchem.4c00015

IF: 8.039

2024-04-26

Journal of Medicinal Chemistry

Abstract:DNA damage response (DDR) defects in cells play a crucial role in tumor development by promoting DNA mutations. These mutations create vulnerabilities specific to cancer cells, which can be effectively targeted through synthetic lethality-based therapies. To date, numerous small molecule DDR inhibitors have been identified, and some of them have already been approved for clinical use. However, due to the complexity of the tumor microenvironment, mutations may occur in the amino acid residues of...

chemistry, medicinal
DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies

Marwan Kwok,Angelo Agathanggelou,Tatjana Stankovic

DOI: https://doi.org/10.1182/blood.2023019963

IF: 20.3

2024-03-09

Blood

Abstract:The DNA damage response (DDR) encompasses the detection and repair of DNA lesions and is fundamental to the maintenance of genome integrity. Germline DDR alterations underlie hereditary chromosome instability syndromes by promoting the acquisition of pathogenic structural variants in hematopoietic cells, resulting in increased predisposition to hematologic malignancies. Also frequent in hematologic malignancies are somatic mutations of DDR genes, typically arising from replication stress triggered by oncogene activation or deregulated tumor proliferation that provides a selective pressure for DDR loss. These defects impair homology-directed DNA repair or replication stress response, leading to an excessive reliance on error-prone DNA repair mechanisms that results in genomic instability and tumor progression. In hematologic malignancies, loss-of-function DDR alterations confer clonal growth advantage and adverse prognostic impact, but may also provide therapeutic opportunities. Selective targeting of functional dependencies arising from these defects could achieve synthetic lethality, a therapeutic concept exemplified by inhibition of poly(ADP-ribose) polymerase or the ATR-CHK1-WEE1 axis in malignancies harboring the BRCAness phenotype or genetic defects that increase replication stress. Furthermore, the role of DDR defects as a source of tumor immunogenicity, as well as their impact on the crosstalk between DDR, inflammation and tumor immunity are increasingly recognized, thus providing rationale for combining DDR modulation with immune modulation. The nature of the DDR-immune interface and the cellular vulnerabilities conferred by DDR defects may nonetheless be disease-specific and remain incompletely understood in many hematologic malignancies. Their comprehensive elucidation will be critical for optimizing therapeutic strategies to target DDR defects in these diseases.-

hematology
Genetic vulnerabilities upon inhibition of DNA damage response

Chao Wang,Mengfan Tang,Zhen Chen,Litong Nie,Siting Li,Yun Xiong,Klaudia Anna Szymonowicz,Jeong-Min Park,Huimin Zhang,Xu Feng,Min Huang,Dan Su,Traver Hart,Junjie Chen,Klaudia Anna Szymonowicz

DOI: https://doi.org/10.1093/nar/gkab643

IF: 14.9

2021-07-28

Nucleic Acids Research

Abstract:Abstract Because of essential roles of DNA damage response (DDR) in the maintenance of genomic integrity, cellular homeostasis, and tumor suppression, targeting DDR has become a promising therapeutic strategy for cancer treatment. However, the benefits of cancer therapy targeting DDR are limited mainly due to the lack of predictive biomarkers. To address this challenge, we performed CRISPR screens to search for genetic vulnerabilities that affect cells’ response to DDR inhibition. By undertaking CRISPR screens with inhibitors targeting key DDR mediators, i.e. ATR, ATM, DNAPK and CHK1, we obtained a global and unbiased view of genetic interactions with DDR inhibition. Specifically, we identified YWHAE loss as a key determinant of sensitivity to CHK1 inhibition. We showed that KLHL15 loss protects cells from DNA damage induced by ATM inhibition. Moreover, we validated that APEX1 loss sensitizes cells to DNAPK inhibition. Additionally, we compared the synergistic effects of combining different DDR inhibitors and found that an ATM inhibitor plus a PARP inhibitor induced dramatic levels of cell death, probably through promoting apoptosis. Our results enhance the understanding of DDR pathways and will facilitate the use of DDR-targeting agents in cancer therapy.

biochemistry & molecular biology
DNA damage response-related ncRNAs as regulators of therapy resistance in cancer

Ziru Gao,Xinchi Luan,Xuezhe Wang,Tianyue Han,Xiaoyuan Li,Zeyang Li,Peifeng Li,Zhixia Zhou

DOI: https://doi.org/10.3389/fphar.2024.1390300

2024-08-26

Abstract:The DNA damage repair (DDR) pathway is a complex signaling cascade that can sense DNA damage and trigger cellular responses to DNA damage to maintain genome stability and integrity. A typical hallmark of cancer is genomic instability or nonintegrity, which is closely related to the accumulation of DNA damage within cancer cells. The treatment principles of radiotherapy and chemotherapy for cancer are based on their cytotoxic effects on DNA damage, which are accompanied by severe and unnecessary side effects on normal tissues, including dysregulation of the DDR and induced therapeutic tolerance. As a driving factor for oncogenes or tumor suppressor genes, noncoding RNA (ncRNA) have been shown to play an important role in cancer cell resistance to radiotherapy and chemotherapy. Recently, it has been found that ncRNA can regulate tumor treatment tolerance by altering the DDR induced by radiotherapy or chemotherapy in cancer cells, indicating that ncRNA are potential regulatory factors targeting the DDR to reverse tumor treatment tolerance. This review provides an overview of the basic information and functions of the DDR and ncRNAs in the tolerance or sensitivity of tumors to chemotherapy and radiation therapy. We focused on the impact of ncRNA (mainly microRNA [miRNA], long noncoding RNA [lncRNA], and circular RNA [circRNA]) on cancer treatment by regulating the DDR and the underlying molecular mechanisms of their effects. These findings provide a theoretical basis and new insights for tumor-targeted therapy and the development of novel drugs targeting the DDR or ncRNAs.

Custom-made cast titanium implants produced with CAD/CAM for the reconstruction of cranium defects.

Targeting the DNA Repair Pathway for Breast Cancer Therapy: Beyond the Molecular Subtypes.

Ionic conducting lanthanide oxides.

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

DNA Damage Response Inhibitors: an Avenue for TNBC Treatment

Targeting DNA damage response pathways in cancer

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy

Targeting the DNA damage response in hematological malignancies

Targeting DNA Repair Pathways: Mechanisms and Potential Applications in Cancer Therapy

Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity

Abstract IA017: Drugging the DNA damage response (DDR) in the Clinic: Going beyond the approved PARP inhibitors

Abstract MS1-3: Targeting DNA damage response and HRD in breast cancer

DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer

Alterations of DNA damage repair in cancer: from mechanisms to applications

Recent Progress in DNA Damage Response-Targeting PROTAC Degraders

DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies

Genetic vulnerabilities upon inhibition of DNA damage response

DNA damage response-related ncRNAs as regulators of therapy resistance in cancer